<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050124</url>
  </required_header>
  <id_info>
    <org_study_id>19-00437</org_study_id>
    <nct_id>NCT04050124</nct_id>
  </id_info>
  <brief_title>Impact of Prisma on Donor Site Pain</brief_title>
  <official_title>Impact of Promogran Prisma™ on Pain of Split-thickness Skin Graft Donor Sites Compared to Standard of Care Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility of evaluating the use of a composite
      collagen, silver-oxidized regenerated cellulose matrix compared to the standard of care
      dressing on donor site pain for patients undergoing split-thickness skin grafting in
      preparation for a larger study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Score between treatment and control arms</measure>
    <time_frame>Day 1</time_frame>
    <description>The primary endpoint of this feasibility study is to evaluate if using Promogran in addition to SOC is associated with a clinically meaningful difference in pain score (≥2 points on the pain scale) between the treatment and control arms on postoperative day (POD) 1.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Skin Graft Disorder</condition>
  <condition>Donor Site Complication</condition>
  <arm_group>
    <arm_group_label>Promogran Prisma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following standard of care split thickness skin grafting, patients randomized to the intervention group will receive Promogan Prisma as the primary contact dressing at the donor grafting site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care (SOC) dressings</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Promogran Prisma</intervention_name>
    <description>Promogran+SOC; composite collagen, silver-oxidized regenerated cellulose matrix</description>
    <arm_group_label>Promogran Prisma</arm_group_label>
    <arm_group_label>Standard of care (SOC) dressings</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care (SOC) dressings</intervention_name>
    <description>standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.</description>
    <arm_group_label>Promogran Prisma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient scheduled to undergo STSG for any reason

          -  Patient, or designated healthcare proxy, has read and signed the IRB-approved informed
             consent form.

        Exclusion Criteria:

          -  Active infection or history of radiation to the donor site

          -  Patient has a known sensitivity to Promogran Prisma™ or silver

          -  Elevated INR &gt;3.0

          -  Insensate at the donor site

          -  Chronic narcotic use (&gt;6 months of daily use)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Donor site pain after skin graft harvesting</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

